Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sivelestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE known ✓ | P08246 | 16/20 | 0.69 |
| ▸ | PRTN3 | P24158 | 12/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sivelestat SCHEMBL1499929 | 0.99 | ELANE (0.68) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL597819 | 0.99 | ELANE (0.68) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL4411781 | 0.99 | ELANE (0.71) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL28751433 | 0.99 | ELANE (0.71) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL123221 | 0.99 | ELANE (0.71) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL30864380 | 0.98 | ELANE (0.69) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL6690886 | 0.98 | ELANE (0.69) | ELANEPRTN3NPC1RAB9AKDM4E | |
| SCHEMBL7267891 | 0.91 | ELANE (0.71) | ELANEPRTN3KDM4EGAAHSD17B10 | |
| SCHEMBL9777074 | 0.90 | ELANE (0.69) | ELANEPRTN3NPC1KDM4EGAA | |
| Sivelestat SCHEMBL4411778 | 0.90 | ELANE (0.69) | ELANEPRTN3NPC1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076936-A1 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION OF SIVELESTAT OR SALT THEREOF AND PREPARATION METHOD THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2026-03-19 | — | — | US | claimed |
| US-20250262230-A1 | HMGB1 Inhibitors for Treatment of APOE4-related Tauopathies including Alzheimer’s Disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-08-21 | — | — | US | claimed |
| EP-4543459-A1 | HMGB1 INHIBITORS FOR TREATMENT OF APOE4-RELATED TAUOPATHIES INCLUDING ALZHEIMER'S DISEASE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2025-04-30 | — | — | EP | claimed |
| CN-119139267-B | Platelet membrane coated nano-particles and application thereof in preparation of medicines for treating sepsis-related acute lung injury | 苏州大学附属儿童医院 | 2025-03-11 | — | — | CN | claimed |
| CN-119139267-A | Platelet membrane coated nano-particles and application thereof in preparation of medicines for treating sepsis-related acute lung injury | 苏州大学附属儿童医院 | 2024-12-17 | — | — | CN | claimed |
| US-20240082203-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION | Shanghai Huilun Pharmaceutical Co., Ltd. (CN) | 2024-03-14 | — | — | US | claimed |
| WO-2023250249-A1 | HMGB1 INHIBITORS FOR TREATMENT OF APOE4-RELATED TAUOPATHIES INCLUDING ALZHEIMER'S DISEASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2023-12-28 | — | — | WO | claimed |
| EP-4272736-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION | Shanghai Huilun Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | claimed |
| WO-2022143722-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION | 上海汇伦生物科技有限公司 | 2022-07-07 | — | — | WO | claimed |
| CN-107913261-A | A kind of sivelestat sodium Foradil Aerolizer formoterol fumarate and preparation method thereof | 郑州泰丰制药有限公司 | 2018-04-17 | — | — | CN | claimed |
| US-20150087605-A1 | Compositions and Methods Comprising Carboxylic Acid-Containing Small Molecules | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2015-03-26 | — | — | US | claimed |
| CN-104107172-A | Preparation method of sivelestat sodium lyophilized powder for injection | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO LTD | 2014-10-22 | — | — | CN | claimed |
| CN-104045587-A | New synthetic method of sivelestat sodium hydrate | ANHUI HERYI CHEMICALS CO LTD | 2014-09-17 | — | — | CN | claimed |
| CN-104045586-A | Preparation method of sivelestat sodium hydrate intermediate | ANHUI HERYI CHEMICALS CO LTD | 2014-09-17 | — | — | CN | claimed |
| CN-101575306-B | Method for preparing sivelestat sodium | SHANGHAI YOUSHOU MEDICAL TECHNOLOGY DEV CO LTD | 2012-11-21 | — | — | CN | claimed |
| CN-101575306-A | Method for preparing sivelestat sodium | SHANGHAI YOUSHOU MEDICAL TECHN (CN) | 2009-11-11 | — | — | CN | claimed |
| CN-100448442-C | Use of elastic protease inhibitor for preparing medicine for protecting cerebral hemorrhage | CHONG PHARMACEUTICAL INDUSTRY (CN) | 2009-01-07 | — | — | CN | claimed |
| CN-1813706-A | Use of elastic protease inhibitor for preparing medicine for protecting cerebral hemorrhage | CHONG PHARMACEUTICAL INDUSTRY (CN) | 2006-08-09 | — | — | CN | claimed |
| US-20020022738-A1 | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-02-21 | — | — | US | claimed |
| EP-1166773-A1 | Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262230-A1 | HMGB1 Inhibitors for Treatment of APOE4-related Tauopathies including Alzheimer’s Disease | HMGB1, HMGB2, HMGB3 | ELANE 1241/4885PRTN3 706/4885NPC1 124/4885 |
| US-20260076936-A1 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION OF SIVELESTAT OR SALT THEREOF AND PREPARATION METHOD THEREOF | SERPINB1, ELANE, PLA2G2D | ELANE 2/4885PRTN3 393/4885NPC1 1642/4885 |
| US-20020022738-A1 | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof | SLC6A5, ABCB11, SLC6A1 | ELANE 4496/4885PRTN3 3836/4885NPC1 2119/4885 |
| US-20150087605-A1 | Compositions and Methods Comprising Carboxylic Acid-Containing Small Molecules | ANTXR2, AADAC, HAAO | ELANE 832/4885PRTN3 1515/4885NPC1 3631/4885 |
| US-20240082203-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION | AQP1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AQP4 | ELANE 3681/4885PRTN3 3578/4885NPC1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.